Prevalentie van epilepsie en slaapstoornissen in de ziekte van Alzheimer.
From 01-10-2018 to 30-09-2022
Description
Alzheimer’s disease (AD) is the most common neurodegenerative disease causing dementia, and one of the leading causes of death1. Currently, there is no curative therapy for AD. In view of the aging population, dementia is becoming a major health issue, with an important impact on society and a heavy burden on health financing in Belgium2. Epilepsy and sleep-wake disturbances are common co-morbid conditions in AD, which may be responsible for progressive Attachment 3, W Van Paesschen et al, epilepsy and sleep-wake disturbances in Alzheimer’s disease, 2 deterioration of AD. They affect cognition, behavior and caregiving, and are cited as the main reason to institutionalize the elderly. Therefore, they have a huge impact on the economical and societal burden of dementia. Epilepsy and sleep-wake disturbances are, however, the most underestimated issues in dementia, and thus also the field where we can help patients and caregivers the most. Our aim is to develop a wearable tool for reliable, multimodal electro-encephalography (EEG) and sleep monitoring in the home setting. As wearable sensor technologies for physiological signals are currently not accurate enough for medical purposes (but will be improved significantly in the coming years by hardware manufacturers), we will first focus in this project on clinical knowledge insights and algorithm development for automated data processing based on standard measurement equipment for hospital/home monitoring. This will allow us in a later phase to follow large cohorts over prolonged times and thus obtain the first clear and complete map of epilepsy and sleep-wake disturbances in patients with AD. Our ultimate goal is to improve the outcome of patients with AD by early treatment of epilepsy and restoring sleep-wake disturbances.
Team
- Maarten De Vos, Co-promoter
- Wim Van Paesschen, Coordinator (External)
- Steven Vandeput, Proposal Manager
- Sabine Van Huffel, Team member
Financing
Funding: KU Leuven - Internal Funding KU Leuven
Program/Grant Type: C2 - KU Leuven Category 2 Funding
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.